Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don’t see a real reason for that to happen on Monday. Tea leaves won’t cut it at this late stage.
Not radiology, radiation oncology. 2 completely different specialties.
I have to agree. I highly doubt anything is being delayed over this. Maa was submitted and is out of the company’s hands. Now do they start manufacturing immediately upon approval with manual production if say the flask works decide happens to be ready soon? That’s a different question but not relevant to us today.
We are waiting on the mhra, it’s that simple.
Sorry when do you think we hear a decision from mhra? Optimistically, pessimistically and realistically.
Eureka!!!! Those stupid jama editors. Such low standards I tell you.
Horrible disease. I hope dcvax plus pdl1 can help many of these patients in the not too distant future. It’s a fucked up world where peer reviewed data in jama isn’t enough to help a tiny company overcome greedy big money in a more timely fashion.
We will get there eventually but many people will die in the meantime.
Please stop with this speculation stuff. Eden is not part of the submission.
Yeh I agree. Your post is a Hail Mary.
Better tell the jama editors they were wrong.
Lol
Yes. There has been no change in the standard of care for 30 years. DCVax is not an approved treatment as of February 2024 and so his statement is correct in the context of standard of care.
Nice try
That is an opinion commentary in a 3rd tier journal whereas the jama paper is original peer reviewed research accepted in a 1st tier journal.
One is backed by data and with one of the highest stamps of approval, the other is a consolation prize to a few conflicted physicians who stand to lose income if dcvax is approved.
I guess the jama reviewers and editors don’t know anything about ECAs, inclusion exclusion criteria and stats. Makes sense. What are they? 3rd or 4th tier journal?
Good to hear from you again. I agree with you but at some point you have to ask yourself why the sp is where it is. It’s hard to pin it 100% on the dark side.
That’s why I am not adding even though price is 20 percent below my average and in the past I have averaged down. Enough is enough. I need to sell some not buy some. Hopefully we get something soon that at least brings this back up to 60s-80s. These past few days have been painful.
Is it a coincidence that price is dropping around the CHM meeting days? Manipulation to scare us or is it possible someone big got wind of something negative? The volume has not been low these past few days so seems like someone is selling.
I have a million shares, down 20 percent now. Just can’t bring myself to put more in. It’s already way too much. I hope I regret it soon. This is very painful.
Was their success published in jama?
Minor detail right?
Yes there was actually.
Nonsense
Yeh, placebo effect in GBM. Aha. Definitely a possibility.
Agreed. Hopefully approval changes things.
Stick around junior. Watch and learn.
Sure you do
Actually those were all warrant conversions so whether that happens now or later it’s happening and the price has been set.
Overpromise under deliver
They submitted to mhra and hope to qualify for the 150 day review. Isn’t that an outlook?
False, not nature
This is NOT a nature article. It is an open access review in a mediocre journal.
There is no nature article. Please stop repeating this nonsense.
Even a broken clock is right 12 times a day ;)
And what’s your goal?
Said the man who said
No journal article
No MAA submission
What a joke
Low life individuals?
That’s rich coming from you. How’s the lawsuit coming?
Please show me where the Germans made this comment.
Thanks
I don’t buy your overly optimistic interpretation of the halt. If regulators were so confident in the data to recommend a halt for efficacy they would have also given assurances of approval. It’s much more logical that regulators saw PFS was failing and recommended a halt but also realized the potential of OS and pseudoprogression so “allowed” the company to “continue” the trial and change the end points but not treat new patients.
They are lawyers and masters of words. If that were the case the PR would have stated that the submission was accepted or validated not that the company submitted.
I agree with that but a company has a fiduciary responsibility to its shareholders (the owners of the company). I understand that we are in murky waters when discussing this, truly I do. But I honestly think that the average reasonable bystander/investor would not stay invested through all these years given what we knew in real time. If the company had information that could, legally, have been shared I think we had a right to know in order to make informed decisions. The argument that we will keep it secret from you because it’s best for the company is a dangerous one that can and has been used to hide adverse information in countless prior examples throughout the course of human history. “Trust me” is not fiduciary responsibility.
The longs that have stayed strong and even doubled and quadrupled down (especially to the degree that I have) are in some ways bad investors. In fact I have long been labeled as a hopeless dreamer by essentially everyone I know because of this investment. People don’t even argue with me anymore, they have given up. My wife has started playing the lottery and when I explain to her the statistics of it she points to my “success” with nwbo as a counter argument (thank god she doesn’t comprehend the scale…).
Nice guy. Go have a beer and relax a bit.
That doesn’t help long term shareholders who are losing or have lost faith. This is a public company not a cult driven by blind faith. In fact if what you say is true then the ‘reasonable’ investors who sold when the price crashed from 12 to 0.14 lost out even though their investment helped carry this company to the end of the trial. The company owes those people. By keeping the silence during the crash (assuming they held positive information as you claim) they hung those people out to dry.
EMA and MHRA are not the same body…